Progress in EscharEx VLU Trial
Enrollment in the VALUE Phase III trial for EscharEx, targeting venous leg ulcers, is advancing with strong support from previous Phase II results. The trial's co-primary endpoints include complete debridement and wound closure.
Expansion of NexoBrid Manufacturing
MediWound completed the commissioning of an expanded NexoBrid manufacturing facility, increasing production capacity by six times, aiming to meet rising global demand.
Financial Strengthening
The balance sheet was strengthened with $30 million of equity financing, increasing cash reserves to $60 million as of September 30, 2025.
Revenue Growth
Revenue for the third quarter was $5.4 million, a 23% increase year-over-year, driven by higher development services revenue.
NexoBrid U.S. Market Performance
NexoBrid achieved record quarterly revenue in the U.S., with a 38% year-over-year increase and 26% sequential growth.